Caribou Biosciences Stock Forecast
NASDAQ: CRBUHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CRBU analyst consensus
Consensus (6 analysts)
buy
Avg. price target
$5.75+1149.46%
- Strong buy 0
- Buy 2
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 6 Wall Street analysts covering Caribou Biosciences (2026-10-09), 2 rate the stock a buy or strong buy, 4 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $5.75, with a high estimate of $13.00 and a low estimate of $1.00. The average target implies upside of 1149.5% from the current price of $0.4602.
The spread between the highest and lowest targets is 1200.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for CRBU.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 2 | 33% |
| Hold | 4 | 67% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $1.00 | +117.30% |
| Average target | $5.75 | +1149.46% |
| High target | $13.00 | +2724.86% |